Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation ExpenseEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsShares Issued
Ratios

Akebia Therapeutics (AKBA) Depreciation Expense (2019 - 2025)

Historic Depreciation Expense for Akebia Therapeutics (AKBA) over the last 6 years, with Q3 2025 value amounting to $318000.0.

  • Akebia Therapeutics' Depreciation Expense fell 1239.67% to $318000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 1564.76%. This contributed to the annual value of $1.5 million for FY2024, which is 776.03% down from last year.
  • Akebia Therapeutics' Depreciation Expense amounted to $318000.0 in Q3 2025, which was down 1239.67% from $316000.0 recorded in Q2 2025.
  • Over the past 5 years, Akebia Therapeutics' Depreciation Expense peaked at $408000.0 during Q4 2022, and registered a low of $314000.0 during Q1 2025.
  • Over the past 4 years, Akebia Therapeutics' median Depreciation Expense value was $379000.0 (recorded in 2023), while the average stood at $366916.7.
  • As far as peak fluctuations go, Akebia Therapeutics' Depreciation Expense skyrocketed by 75.57% in 2024, and later plummeted by 2100.0% in 2025.
  • Quarter analysis of 4 years shows Akebia Therapeutics' Depreciation Expense stood at $408000.0 in 2022, then fell by 3.43% to $394000.0 in 2023, then fell by 14.97% to $335000.0 in 2024, then fell by 5.07% to $318000.0 in 2025.
  • Its Depreciation Expense stands at $318000.0 for Q3 2025, versus $316000.0 for Q2 2025 and $314000.0 for Q1 2025.